OncoMatch/Clinical Trials/NCT04774419
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Is NCT04774419 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dostarlimab for endometrial cancer.
Treatment: Dostarlimab — This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Endometrial Cancer
Biomarker criteria
Required: MMR deficient
MMR-D
Required: MSI high
MSI-H
Required: POLE mutation
POLE-mutated
Required: MLH1 promoter hypermethylation
hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2)
Required: MSH2 promoter hypermethylation
hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2)
Required: MSH6 promoter hypermethylation
hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2)
Required: PMS2 promoter hypermethylation
hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2)
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery — endometrial cancer
Must have undergone a complete surgical staging
Cannot have received: chemotherapy
Exception: Patients who have received prior chemotherapy, targeted therapy, or other investigational therapies for other cancers and are in remission/cured may be included at the discretion of the treating investigator in consultation with the study PI.
Has had prior chemotherapy, targeted therapy, or investigational therapy for endometrial cancer.
Cannot have received: targeted therapy
Exception: Patients who have received prior chemotherapy, targeted therapy, or other investigational therapies for other cancers and are in remission/cured may be included at the discretion of the treating investigator in consultation with the study PI.
Has had prior chemotherapy, targeted therapy, or investigational therapy for endometrial cancer.
Cannot have received: investigational therapy
Exception: Patients who have received prior chemotherapy, targeted therapy, or other investigational therapies for other cancers and are in remission/cured may be included at the discretion of the treating investigator in consultation with the study PI.
Has had prior chemotherapy, targeted therapy, or investigational therapy for endometrial cancer.
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent for endometrial cancer.
Cannot have received: anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent for endometrial cancer.
Cannot have received: anti-CTLA-4 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent for endometrial cancer.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,500 /mcL; Platelets ≥100,000 / mcL; Hemoglobin ≥9 g/dL
Kidney function
Creatinine Clearance GFR ≥ 45
Liver function
Serum total bilirubin ≤ 1.5 X ULN (patients with known Gilbert's disease Serum total bilirubin who have bilirubin level ≤ 3 x ULN may be enrolled); AST and ALT ≤ 3 ULN OR ≤ 5 X ULN for subjects with liver metastases
Demonstrate adequate organ function as defined below. All screening labs should be performed within 14 days of treatment initiation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All Protocol Activites) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04774419 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MMR?
Yes, MMR deficient is a required biomarker for enrollment.
Does this trial require MSI?
Yes, MSI high is a required biomarker for enrollment.
Does this trial require POLE?
Yes, POLE mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify